Lynch Regenerative Medicine: What PDGF Technology Means in 2026
Introduction: Why “Lynch Regenerative Medicine” Keeps Showing Up in Your Search Results
Many people who search for “Lynch Regenerative Medicine” expect to find a clinic with a booking page, a list of treatments, and a phone number for scheduling. Some saw the name on a med-spa menu. Others heard it from a dermatologist or a wound-care specialist. A few came across it in an investment newsletter.
The most important fact comes first: Lynch Regenerative Medicine (LRM) is a biotech and product company based in Franklin, Tennessee. It is not a direct-to-patient provider. Patients cannot book an appointment with LRM the way they would with a medical practice.
That clarification is only the starting point. The name appears so often because it is tied to a specific, well-studied technology: platelet-derived growth factor, known as PDGF-BB. That science has a regulatory track record of more than 15 years that few brands in regenerative medicine can match. This article explains what PDGF-BB is, how products built on it reached the market, and how patients can interpret the Lynch name when they see it on a provider’s treatment menu. It also covers the FDA framework that separates rigorously reviewed regenerative products from the much larger pool of lightly regulated offerings, which is the knowledge patients most need.
What Lynch Regenerative Medicine Actually Is
Lynch Regenerative Medicine, LLC is headquartered at 302 Innovation Drive, Suite 500, Franklin, TN 37067. The company describes itself as a global leader in growth factor medicine. Its work centers on PDGF research and on turning that research into wound-healing medications and skincare applications.
Its business model works behind the scenes. LRM develops PDGF-BB technology that is licensed, formulated, or sold for use inside products that other companies and healthcare providers use. When a patient receives a treatment involving LRM technology, a separate clinician or practice administers it. LRM supplies the ingredient and the science; it does not operate the clinic.
The company was founded in 2023. It is a young organization in name only, since it builds on decades of earlier work by its founder.
The Man Behind the Name: Dr. Samuel Lynch
Dr. Samuel Lynch, DMSc, DMD, holds a Doctorate of Medical Sciences from Harvard Medical School and a Doctorate of Dental Medicine with a specialty in periodontology. His education spans biomedical research and clinical practice, two areas that rarely overlap so fully in one career.
He is a serial entrepreneur in regenerative medicine. Before LRM, he founded Lynch Biologics and BioMimetic Therapeutics, both of which advanced growth factor technology toward clinical use. He has authored more than 250 publications and patents. The American Academy of Periodontology has described him as “one of the world’s foremost authorities on growth factors to tissue regeneration.”
This background matters for patients and researchers. Many regenerative medicine startups enter the market with a promising idea and little regulatory history. LRM’s technology comes from a founder who has repeatedly taken growth factor science through laboratory development, clinical trials, and FDA review. That record gives the company a degree of scientific and regulatory credibility that is uncommon in the field.
The Science: What PDGF-BB Is and How It Drives Tissue Regeneration
Platelet-derived growth factor (PDGF) is a protein the body produces naturally. Its main job is signaling: it tells certain cells to grow, multiply, and move to where tissue needs repair. PDGF-BB is one specific form of this protein, and it is the form most closely studied for therapeutic use.
When the body is injured, platelets gather at the site and release growth factors, including PDGF. This begins the wound-healing cascade. PDGF-BB helps recruit and activate cells that rebuild damaged tissue, and it stimulates the deposit of extracellular matrix, the structural scaffolding that gives repaired tissue its form and strength. Without enough matrix, new tissue cannot properly fill in a wound or restore what was lost.
Therapeutic PDGF-BB is produced in recombinant (laboratory-manufactured) or purified form. This differs from approaches that try to collect a patient’s own growth factors from blood. A pure, recombinant protein gives clinicians a controlled, concentrated, and reproducible input. Every dose contains the same molecule at a known concentration, which is difficult to achieve with biological material drawn from individual patients.
Why PDGF-BB Specifically, Not Just “Growth Factors” in General
Many treatments are marketed under the broad label of “growth factors” or “regenerative therapy.” Two common examples are:
- Platelet-rich plasma (PRP): A concentrate made from a patient’s own blood. It contains a mix of growth factors, but the amounts vary by person, by preparation method, and even by the day the blood is drawn.
- Stem cell injections: Products made from various cell sources, often with variable composition and less standardized characterization.
These approaches are not necessarily ineffective, but they are harder to standardize. A single, well-characterized protein such as PDGF-BB allows predictable dosing and rigorous clinical study. Researchers can measure exactly what was given and compare results across large, controlled trials. This is a key reason PDGF-BB has supported FDA-approved products while many other “regenerative” offerings have not.
PDGF-BB applications cover three main areas:
- Orthopedic tissue (bone and related structures)
- Periodontal tissue (the gums and supporting structures of the teeth)
- Skin healing and regeneration (chronic wounds and aesthetic recovery)
From Lab to Patient: 15+ Years of FDA-Approved PDGF Products
The common thread in LRM’s story is this: PDGF-based technology developed by Dr. Lynch is the active component in four FDA-approved products, used in millions of patients over roughly 15 years and longer. These products cover orthopedic, periodontal, and skin applications.
This track record, rather than marketing language, is what sets LRM’s lineage apart. Many regenerative medicine brands that patients see today have never gone through a full premarket FDA review. PDGF technology from Dr. Lynch’s work has gone through it repeatedly.
Regranex: The Original PDGF Success Story
Regranex (becaplermin) gel 0.01% was first approved by the FDA in December 1997 and was originally launched by Dr. Lynch. Published clinical literature describes it as the only FDA-approved growth factor for treating diabetic neuropathic foot ulcers, and its former marketer called it the first and only FDA-approved recombinant PDGF therapy for that use.
Indication: Regranex is approved as an adjunct to standard care for lower-extremity diabetic neuropathic ulcers that extend into subcutaneous tissue and have an adequate blood supply. It is meant to work alongside good wound care practices such as debridement, offloading pressure, and infection control. It does not replace them.
Safety history: In 2008, the FDA added a boxed warning to Regranex about malignancy-related mortality. Over the following decade, several postmarket studies examined the concern and found no increased safety risk. In 2018, the FDA approved removal of the boxed warning. This is a useful example of long-term regulatory oversight: an approved product stayed under review for years, and its labeling changed as new evidence emerged.
Full circle: In 2025, LRM acquired Regranex and created LRM Therapeutics to manage the brand. The product that Dr. Lynch first brought to market in the 1990s is once again managed by its original developer.
ariessence and LRM Aesthetics: PDGF Enters Skincare
In 2023, the company created LRM Aesthetics to bring pure PDGF to the skincare and aesthetics market. Its product, ariessence, is a topical post-treatment product designed to support skin healing and regeneration after aesthetic procedures, such as treatments that intentionally injure the skin to prompt renewal.
This is where many consumers first see the Lynch name. A patient booking a skin procedure at a med spa or dermatology practice may find ariessence listed as an add-on or part of an aftercare protocol. That listing reflects a product the provider uses. It does not mean the clinic is LRM, or that LRM operates the clinic. Patients should also ask their provider about the regulatory status of any aesthetic aftercare product, because skincare products are not necessarily held to the same approval standards as the prescription biologic Regranex.
The Regulatory Story: Why 351 vs. 361 Matters More Than Most Patients Realize
To understand why the Lynch lineage stands out, patients need to know how the FDA regulates regenerative products. The agency uses a two-tier framework for products made from human cells and tissues, and the same thinking shapes how patients should judge any PDGF, PRP, or cell-based therapy they are offered.
The contrast is simple. LRM’s flagship therapeutic, Regranex, went through the more rigorous biologics pathway, and other products in the PDGF lineage went through full premarket FDA review. Many clinics in the wider regenerative medicine market, by contrast, operate under a lighter framework that requires no proof of effectiveness before treatments are offered.
Section 351: Biologic Drugs Requiring Full FDA Approval
Products regulated under Section 351 of the Public Health Service Act are treated as biologic drugs. Before they can be marketed, they must go through the Investigational New Drug (IND) process for clinical testing and then receive a Biologics License Application (BLA) approval.
This pathway requires clinical trial data showing both safety and efficacy before a product reaches patients. Regranex followed this route. The process can take years and involves controlled studies, manufacturing inspections, and continued postmarket monitoring, as the Regranex boxed-warning history shows.
This standard is much higher than many patients assume when they hear the phrase “regenerative medicine.”
Section 361: Minimally Manipulated Products Without Premarket Approval
The second tier covers 361 HCT/Ps (human cells, tissues, and cellular and tissue-based products). A product can qualify for this lighter framework when it is minimally manipulated and used for a homologous purpose, meaning it performs the same basic function in the recipient that it performed in the donor. These products do not require premarket approval.
The FDA’s guidance on HCT/P regulation states that establishments manufacturing 361 HCT/Ps must register and list their products with the agency, and they must follow rules meant to prevent the spread of communicable disease. Registration is not the same as approval. A registered 361 product has not been shown in FDA-reviewed trials to work for any particular condition.
The size of this issue is large. An estimated 30,000 or more U.S. clinics offer regenerative or stem-cell-type treatments outside current FDA-approved indications, often relying on this less stringent tier or operating beyond it. As a result, oversight, evidence quality, and patient outcomes vary widely across the industry.
Why This Distinction Is the Real Takeaway from the Lynch Name
Products carrying Dr. Lynch’s PDGF technology have a documented history of rigorous FDA premarket review, including full biologics approval for Regranex. That is not the norm in the broader regenerative medicine industry.
For patients, the most useful thing to carry into any provider conversation is a simple question: Is this treatment an FDA-approved biologic or device for my condition, or is it a 361 product (or an unapproved offering) that has never been through premarket review? The answer says a great deal about how much evidence supports what is being recommended.
If You’ve Seen “Lynch” or PDGF-BB on a Treatment Menu: What to Ask Your Provider
Seeing the Lynch name on a provider’s menu, such as ariessence after a skin procedure or a PDGF-based wound-care product, means the provider is using a licensed, science-backed ingredient. It does not mean the provider is affiliated with LRM, endorsed by it, or vetted by it.
Patients can ask a few practical questions:
- Is this product FDA-approved, and for what indication? Approval for one condition does not automatically support use for another.
- Is this a 351 biologic, a device, a cosmetic, or a 361 tissue product? Each category carries a different level of regulatory scrutiny.
- What clinical evidence supports using it for my specific condition? Patients should ask for published studies, not testimonials.
- How will results be measured, and what are the alternatives? A responsible provider will explain standard-of-care options alongside any regenerative add-on.
Recognizing the Lynch or PDGF name is a useful signal about the ingredient’s pedigree. Patients should still evaluate the provider separately: confirming board certification and state licensure, asking about experience with the procedure, and watching for red flags such as guaranteed results or vague answers about regulatory status.
The Business Behind the Science: Funding and Market Context
This section is for investors and industry researchers rather than patients.
LRM completed a Series A financing round in July 2024, led by Champion VC, a family office that manages assets for members of the Frist family of Nashville, Tennessee. The company later reached Series B status, with total funding of roughly $15 million as of 2026. Its two operating arms, LRM Aesthetics and LRM Therapeutics, give it a presence in both consumer-facing skincare and prescription wound care.
The broader market is growing quickly. Depending on the research firm, the global regenerative medicine market is valued at roughly $48 to $54 billion in 2026. Most forecasts project growth to well over $90 to $150 billion by the early to mid-2030s, at double-digit compound annual growth rates. One widely cited estimate projects the market rising from about $48.3 billion in 2026 to about $90 billion by 2030. In a field crowded with lightly regulated offerings, companies with established regulatory histories hold a distinctive position.
Conclusion: Turning a Confusing Search Into a Clearer Understanding
Lynch Regenerative Medicine is not a clinic to book. It is a biotech company whose PDGF-BB technology underlies real, FDA-reviewed products used in wound care, periodontal, orthopedic, and aesthetic applications. Its founder’s career spans Harvard training, more than 250 publications and patents, and several FDA-approved products, from the first approval of Regranex in 1997 to its reacquisition in 2025.
The more lasting lesson reaches beyond one brand. Knowing the difference between 351 biologics and 361 tissue products prepares patients to judge any regenerative treatment they are offered. Dr. Lynch’s scientific and regulatory record provides a useful benchmark: when evaluating any regenerative product, patients can ask whether it has met a comparable standard of evidence.
Next Steps for Patients and Researchers
- Patients: If a PDGF-based product appears in a treatment plan, ask the provider directly about its FDA status, its approved indication, and the clinical evidence behind it for the condition in question.
- Investors and industry observers: Keep following LRM’s corporate developments, including funding rounds, product acquisitions, and growth in its therapeutics and aesthetics divisions.
- All readers: Explore related educational content on this site about how to vet regenerative medicine providers more broadly. With a working knowledge of the 351 vs. 361 framework, readers are well prepared to separate evidence-based care from marketing.
